At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 142 enrolled
Drug / intervention
LDX +1 moredrug
Likely dose
LDX 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
In Brief
A Phase 3 clinical trial evaluating LDX and Placebo for ADHD. Completed, enrolled 142 participants across 5 sites.
Detailed Summary
To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsADHD
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJul 2008
Primary CompletionDec 2008
TodayJul 2026
First PostedJun 16, 2008
Enrollment StartJul 18, 2008
Primary CompletionDec 20, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.0 years ago
Interventions
LDXdrug
oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
Placebodrug
Placebo administered once-daily for one week during the adult workplace environment setting